• No reports of granuloma formation associated with PRIALT *
• Does not invoke the debilitating adverse events associated with opioid therapy
• PRIALT does not interact with opiate receptors and does not cause opiate-induced respiratory depression  

A Proven safety profile: PRIALT has been evaluated in more than 1,200 patients, over 662 patient years.

• PRIALT has been administered as a continuous IT infusion in 1,254 patients over three double-blind, placebo controlled, multi-center studies and four open-label, long-term studies
• Duration of treatment lasted more than 7.5 years (mean duration: 193 days)
• Most commonly reported adverse events ( 25%) in the clinical trials were dizziness, nausea, confusional state, and nystagmus
• Serious adverse events and discontinuations for adverse events were less frequent when PRIALT was titrated slowly   

Incidence of Treatment-Emergent Adverse Events in Placebo-Controlled Study that Occurred in 5% of patients and were more common with PRIALT than with placebo

*Deer et. al. Polyanalgesic Consensus Panel 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007; 10:300-328.